These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18290771)

  • 21. Differential relationships between basal and post-load insulin resistance indices and hepatic fibrosis in chronic hepatitis C and in non-alcoholic fatty liver disease.
    Targher G; Zoppini G; Muggeo M
    Gut; 2008 Mar; 57(3):426; author reply 426-7. PubMed ID: 18268061
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma.
    Chen CH; Lin ST; Kuo CL; Nien CK
    Hepatogastroenterology; 2008; 55(85):1423-7. PubMed ID: 18795704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data.
    Serfaty L; Capeau J
    Liver Int; 2009 Mar; 29 Suppl 2():13-25. PubMed ID: 19187069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus and glucose and lipid metabolism.
    Alaei M; Negro F
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):692-700. PubMed ID: 19195632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection?
    Sanai FM; Benmousa A; Al-Hussaini H; Ashraf S; Alhafi O; Abdo AA; Alameri HF; Akbar HO; Bzeizi KI
    Liver Int; 2008 Aug; 28(7):1011-8. PubMed ID: 18384520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Utility of 2 biochemical models predictive of liver fibrosis grade in prison inmates with hepatitis C].
    Portilla J; López-Burgos A; Saiz-De-La-Hoya-Zamácola P; Sánchez-Payá J; Bedía-Collantes M; Faraco-Atienzar I; Lissen E
    Gastroenterol Hepatol; 2009; 32(6):387-94. PubMed ID: 19477553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?
    Castera L; Denis J; Babany G; Roudot-Thoraval F
    J Hepatol; 2007 Mar; 46(3):528-9; author reply 529-30. PubMed ID: 17239479
    [No Abstract]   [Full Text] [Related]  

  • 28. Liver function critically determines serum retinol-binding protein 4 (RBP4) levels in patients with chronic liver disease and cirrhosis.
    Tacke F; Weiskirchen R; Trautwein C
    Hepatology; 2008 Nov; 48(5):1724-5; author reply 1725-6. PubMed ID: 18972556
    [No Abstract]   [Full Text] [Related]  

  • 29. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.
    van der Poorten D; George J
    Clin Liver Dis; 2008 Nov; 12(4):805-24, ix. PubMed ID: 18984468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Steatosis in chronic viral hepatitis C: frequency, risk factors and relationship with fibrosis].
    Karoui S; Taieb Jomni M; Bellil K; Haouet S; Boubaker J; Filali A
    Tunis Med; 2008 Jul; 86(7):670-5. PubMed ID: 19472729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HCV and steatosis in children.
    Comparcola D; Nobili V; Marcellini M
    J Hepatol; 2006 Nov; 45(5):758; author reply 758-9. PubMed ID: 16979775
    [No Abstract]   [Full Text] [Related]  

  • 32. A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans.
    Lemon SM; Lerat H; Weinman SA; Honda M
    Trans Am Clin Climatol Assoc; 2000; 111():146-56; discussion 156-7. PubMed ID: 10881339
    [No Abstract]   [Full Text] [Related]  

  • 33. Metabolic abnormalities in chronic hepatitis C. Introduction.
    Capeau J; Gharakanian S; Younossi ZM
    Liver Int; 2009 Mar; 29 Suppl 2():1-2. PubMed ID: 19187072
    [No Abstract]   [Full Text] [Related]  

  • 34. Assessment of hepatitis C: non-invasive fibrosis markers and/or liver biopsy.
    Bedossa P
    Liver Int; 2009 Jan; 29 Suppl 1():19-22. PubMed ID: 19207962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NASH and HCC.
    Page JM; Harrison SA
    Clin Liver Dis; 2009 Nov; 13(4):631-47. PubMed ID: 19818310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
    Di Marco V; Capra M; Gagliardotto F; Borsellino Z; Cabibi D; Barbaria F; Ferraro D; Cuccia L; Ruffo GB; Bronte F; Di Stefano R; Almasio PL; Craxì A
    Haematologica; 2008 Aug; 93(8):1243-6. PubMed ID: 18556410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of steatosis with fibrosis and necro-inflammation in chronic hepatitis C infection in the absence of confounding factors.
    Zubair A; Mubarik A; Jamal S; Arif A; Khan DA
    J Coll Physicians Surg Pak; 2009 Jul; 19(7):417-20. PubMed ID: 19576148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive monitoring of hepatitis C fibrosis progression.
    Kotlyar DS; Blonski W; Rustgi VK
    Clin Liver Dis; 2008 Aug; 12(3):557-71, viii. PubMed ID: 18625428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV/hepatitis C co-infection and hepatic fibrosis: looking beyond HIV-associated immune suppression; the contribution of hepatic steatosis and insulin resistance.
    Bhagani S
    Gut; 2009 Dec; 58(12):1579-81. PubMed ID: 19923343
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.